Academic literature on the topic 'Cer-001'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cer-001.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cer-001":

1

Zheng, Kang He, Fleur M. van der Valk, Loek P. Smits, Mara Sandberg, Jean-Louis Dasseux, Rudi Baron, Ronald Barbaras, et al. "HDL mimetic CER-001 targets atherosclerotic plaques in patients." Atherosclerosis 251 (August 2016): 381–88. http://dx.doi.org/10.1016/j.atherosclerosis.2016.05.038.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ossoli, A., A. Strazzella, S. Simonelli, D. Rottoli, M. Abbate, C. M. Zoja, J. L. Dasseux, and L. Calabresi. "Remodeling And Catabolism Of Cer-001 In Absence Of Lcat Enzyme." Atherosclerosis 287 (August 2019): e107. http://dx.doi.org/10.1016/j.atherosclerosis.2019.06.312.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Keyserling, Constance H., Ronald Barbaras, Renee Benghozi, and Jean-Louis Dasseux. "Development of CER-001: Preclinical Dose Selection Through to Phase I Clinical Findings." Clinical Drug Investigation 37, no. 5 (February 17, 2017): 483–91. http://dx.doi.org/10.1007/s40261-017-0506-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nicholls, Stephen J., Jordan Andrews, John J. P. Kastelein, Bela Merkely, Steven E. Nissen, Kausik K. Ray, Gregory G. Schwartz, et al. "Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial." JAMA Cardiology 3, no. 9 (September 1, 2018): 815. http://dx.doi.org/10.1001/jamacardio.2018.2121.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Li, Chen, Pan Pan Wu, and Kun Zhang. "Preparaitve Separation and Purification of Cordycepin from Cultured Cordyceps militaris Using Cation Exchange Resin." Advanced Materials Research 550-553 (July 2012): 1773–78. http://dx.doi.org/10.4028/www.scientific.net/amr.550-553.1773.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
A main active component cordycepin was extracted and purified from cultured Cordyceps militaris. The crude extract was microwave extracted and then purified using a cation exchange resin (CER) of LSD-001. The adsorption ability of the resin was investigated using equilibrium adsorption isotherm including Langmuir and Freundlich model, and the equilibrated relationship between cordycepin and LSD-001 could be well described by Langmuir equation. The influential factors of desorption experiments, such as NH3 concentration, pH value and ethanol content of desorption solution, along with desorption time and temperature were successively investigated. The optimal desorption conditions were confirmed as: 0.2 mol L-1 NH3 combined with 80% ethanol (v/v), desorbed for 2 h at 25 °C and pH 14. Compared with the content in crude C. militaris (2.5 mg g-1), cordycepin in the final purified products (144.6 mg•g-1) was increased 58-fold after one cycle of dynamic adsorption and desorption on resin LSD-001.
6

Flores-Peña, Yolanda, María Eugenia Pérez-Campa, Hermelinda Ávila-Alpirez, Juana Mercedes Gutiérrez-Valverde, and Gustavo Gutiérrez-Sánchez. "Depressive symptoms, maternal feeding styles, and preschool child’s body weight." Salud mental 44, no. 6 (December 2, 2021): 261–66. http://dx.doi.org/10.17711/sm.0185-3325.2021.034.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Introduction. Depressive symptoms (DS) can impact maternal child feeding styles (MCFS), and child’s body weight. Objective. 1. Verify if DS are different depending if the child has, or not, overweight-obesity (OW-OB); 2. Identify the MCFS based on the fact that the child has, or not, OW-OB; 3. Verify it DS are different according to MCFS; 4. Identify DS’s predictors. Method. Correlational cross-sectional study. The participants were 259 dyads (mother- preschool child) residents in Mexico’ Northeast. Mothers answered the Center for Epidemiologic Studies Depression Scale, Revised, and the Caregiver Feeding Styles Questionnaire. Mann-Whitney U test, Chi-square test, Kruskall-Wallis H, and multiple linear regression analysis were performed. Results. Twelve point eight percent of the mothers (n = 33) had DS, 35.5% (n = 92) authoritarian MCFS. No significant difference was identified between DS and MCFS according to the child’s OW-OB or lack thereof (U = 5726.0, p #cer# .05 and X2 = .078, gl = 3, p #cer# .05). A significant positive correlation was found between DS and MCFS demandingness (rs = .208, p = .001). The authoritarian MCFS had the highest DS mean (H = 10.70, gl = 3, p #abr# .05). The demandingness predicts the DS (X2 = 826.445, gl = 1, p = .001). Discussion and conclusion. Authoritarian MCFS predominated, DS were higher in mothers with authoritarian MCFS; demandingness predicts DS. It is recommended to promote authoritarian MCFS which favors the development of healthy eating habits.
7

Faguer, Stanislas, Magali Colombat, Dominique Chauveau, Pauline Bernadet-Monrozies, Audrey Beq, Audrey Delas, Vincent Soler, et al. "Administration of the High-Density Lipoprotein Mimetic CER-001 for Inherited Lecithin–Cholesterol Acyltransferase Deficiency." Annals of Internal Medicine 174, no. 7 (July 2021): 1022–25. http://dx.doi.org/10.7326/l20-1300.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nicholls, Stephen J., Jordan Andrews, John Jp Kastelein, Bela Merkely, Steven E. Nissen, Kausik Ray, Gregory G. Schwartz, et al. "CARAT: will infusing a pre-beta high-density lipoprotein mimetic (CER-001) regress coronary atherosclerosis?" Atherosclerosis 263 (August 2017): e10. http://dx.doi.org/10.1016/j.atherosclerosis.2017.06.060.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ossoli, A., A. Strazzella, D. Rottoli, C. Zanchi, M. Locatelli, C. Zoja, S. Simonelli, et al. "CER-001 ameliorates lipid profile and kidney disease in a mouse model of familial LCAT deficiency." Atherosclerosis 331 (August 2021): e39. http://dx.doi.org/10.1016/j.atherosclerosis.2021.06.112.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Faguer, S., M. Colombat, D. Chauveau, P. Bernadet, A. Delas, V. Soler, I. Labadens, A. Huart, and J. Schanstra. "Place du mimétique HDL CER-001 dans la glomérulopathie secondaire aux déficits en lécithine-cholestérol acyltransférase (LCAT)." Néphrologie & Thérapeutique 17, no. 5 (September 2021): 317–18. http://dx.doi.org/10.1016/j.nephro.2021.07.182.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Cer-001":

1

Begue, Floran. "Lipoprotéines de haute densité (HDL). Implications diagnostiques et thérapeutiques au cours de la COVID 19." Electronic Thesis or Diss., La Réunion, 2024. http://www.theses.fr/2024LARE0002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
Abstract:
Les lipoprotéines de haute densité (HDL) sont essentielles pour une bonne santé cardiovasculaire, grâce notamment à leur transport « inverse » du cholestérol des tissus périphériques au foie pour son élimination. En plus, les HDL exercent de nombreuses autres activités bénéfiques à la fois de type anti-inflammatoire, antioxydant et anti-infectieux. Lors de situations inflammatoires, comme celles rencontrées lors d'infections virales, les HDL peuvent subir des altérations tant quantitatives de baisse de concentration circulantes que qualitatives, comme la modification de composition et perte d'activités protectrices. L'humanité fait toujours face à la maladie au coronavirus (COVID-19) caractérisée par une inflammation aiguë et à l'origine de plus de 6,9 millions de morts dans le monde à ce jour. Aussi, mon travail de thèse a visé la caractérisation des modifications tant quantitative que qualitative des HDL durant la COVID-19, l'identification de biomarqueurs spécifiques de modifications retrouvées dans ces HDL et l'essai thérapeutique d'une supplémentation en HDL mimétique au cours de cette maladie. La quantification des lipoprotéines circulantes dans le plasma de patients atteints de COVID-19 sévère montre une diminution importante d'HDL et d'autres lipoprotéines pouvant constituer autant de biomarqueurs prédictifs de sévérité de la maladie. L'analyse de la distribution des lipoprotéines montre un profil pro-athérogène avec notamment la présence de lipoprotéines de basses densités (LDL) petites et denses dans les plasmas des patients atteints de COVID-19 sévère. L'analyse qualitative par spectrométrie de masse de la composition tant des HDL que des LDL, montre une présence accrue en protéines de la phase aiguë de l'inflammation au détriment de la partie apoprotéïque de ces lipoprotéines quand elles sont isolées de plasma de patients atteints de COVID-19. Testées sur des cellules endothéliales humaines issues de culture primaire, les HDL présentent une altération significative de leurs propriétés anti-apoptotique et anti‑inflammatoire, lorsqu'elles sont purifiées à partir de plasma de patients atteints de COVID‑19. Enfin, des propriétés anti-inflammatoires d'injections d'HDL recombinantes ont pu être mises en évidence chez une patiente admise en réanimation et souffrant d'une forme grave de COVID-19. Pour conclure, mon travail de thèse apporte quelques éléments nouveaux de connaissance sur les modifications des lipoprotéines lors de maladie infectieuse, en l'occurrence la COVID-19. Il ouvre aussi des perspectives prometteuses de recherches pour l'utilisation des HDL à la fois comme biomarqueur de sévérité de maladie inflammatoire que comme moyen de lutte thérapeutique
High-density lipoproteins (HDL) are crucial for maintaining good cardiovascular health due to their ability to transport cholesterol from peripheral tissues to the liver for elimination via a "reverse transport of cholesterol” mechanism. Moreover, HDL exhibits several other advantageous properties, including anti-inflammatory, antioxidant, and anti-infectious activities. In inflammatory situations, such as those encountered during viral infections, HDL can undergo both quantitative alterations, with a drop in circulating concentration, and qualitative alterations, such as a change in composition and loss of protective activities. Humanity is still struggling with coronavirus disease (COVID-19), characterized by acute inflammation and responsible for over 6.9 million deaths worldwide to date. The aim of my thesis was to characterize the quantitative and qualitative changes in HDL during COVID-19, to identify specific biomarkers of the changes found in HDL, and to conduct a therapeutic trial of HDL mimetic supplementation during this disease. Quantification of circulating lipoproteins in the plasma of patients with severe COVID 19 shows a significant decrease in HDL and other lipoproteins, which may be predictive biomarkers of disease severity. Analysis of lipoprotein distribution shows a pro-atherogenic profile, with the presence of small, dense low-density lipoproteins (LDL) in the plasmas of patients with severe COVID-19. Qualitative mass spectrometry analysis of the composition of both HDL and LDL showed an increased presence of proteins from the acute phase of inflammation, to the detriment of the apoprotein part of these lipoproteins when isolated from the plasma of COVID-19 patients. When tested on human endothelial cells from primary culture, HDL demonstrated a significant alteration in their anti-apoptotic and anti-inflammatory properties when purified from the plasma of COVID-19 patients. Finally, the anti-inflammatory properties of recombinant HDL injections were demonstrated in a patient admitted to intensive care with a severe form of COVID-19. In conclusion, my thesis work provides some new insights into lipoprotein modifications during infectious disease, in this case COVID-19. It also opens up promising prospects for research into the use of HDL both as a biomarker of inflammatory disease severity and as a means of therapeutic control

To the bibliography